Beige mouse model for Mycobacterium avium complex disease.
Abstract
Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more» Information about commercial reprint orders: http://aac.asm.org/site/misc/reprints.xhtml To subscribe to to another ASM Journal go to: http://journals.asm.org/site/subscriptions/ ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1995, p. 1647â1654 0066-4804/95/$04.00 0 Copyright 1995, American Society for Microbiology Vol. 39, No. 8 PATTISAPU R. J. GANGADHARAM Mycobacteriology Research Laboratories, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois INTRODUCTION Mycobacterium avium complex (MAC), comprising M. avium, M. intracellulare, and M. scrofulaceum, has been recognized as an important group of organisms causing severe disease in humans, animals, and birds. Soon after AIDS was discovered, it was observed that MAC is also involved in that syndrome as a serious opportunistic infection and is associated with death within 6 to 12 months after diagnosis (12, 52). The clinical management of MAC disease has been difï¬cult and frustrating, since these organisms are resistant to most of the antituberculosis drugs (98). Serious consideration was given to the discovery of effective agents that could be used to cure and prevent this disease, especially in AIDS patients. In the battery of investigations for the identiï¬cation of new chemotherapeutic agents, in vivo tests with suitable animal models